Pathway Genomics’ Cancer Intercept test has a problem


Earlier this month The “New” Prostate Cancer InfoLink stated that the new liquid biopsy test being touted by Pathways Genomics was of no proven value in the diagnosis of prostate cancer and that we expected the U.S. Food and Drug Administration (FDA) would have some comments on the promotion of this test. We were correct.

According to a report on the BloombergBusiness news service, the FDA has told Pathway Genomics that this test is of high risk to healthy individuals, “could harm public health, and hasn’t been validated by science.” To see the FDA’s letter to Pathway Genomics’ CEO, please click here.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: